LON:AVCT Avacta Group (AVCT) Share Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free AVCT Stock Alerts GBX 44.50 -0.10 (-0.22%) (As of 05:07 PM ET) Add Compare Share Share Today's Range 44.30▼ 45.8050-Day Range 44.60▼ 100.5052-Week Range 43.55▼ 166.98Volume4.24 million shsAverage Volume2.58 million shsMarket Capitalization£155.98 millionP/E RatioN/ADividend Yield3.97%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Avacta Group alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Avacta Group Stock (LON:AVCT)Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More AVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVCT Stock News HeadlinesMarch 6, 2024 | finance.yahoo.comUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024December 19, 2023 | finanznachrichten.deAvacta Group: Appointment of Chief Business OfficerApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 19, 2023 | finance.yahoo.comAppointment of Chief Business OfficerDecember 13, 2023 | finance.yahoo.comALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study DataOctober 23, 2023 | finance.yahoo.comAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardSeptember 11, 2023 | msn.comIf I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have nowAugust 11, 2023 | lse.co.ukAvacta Group Share ChatApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.June 21, 2023 | marketwatch.comAvacta Completes Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finanznachrichten.deAvacta Group plc: Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 21, 2023 | finance.yahoo.comAvacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical StudyJune 19, 2023 | marketwatch.comAvacta Group Says No Fundraising Imminent; Shares RiseJune 6, 2023 | uk.finance.yahoo.comAVCT.L - Avacta Group PlcApril 27, 2023 | finance.yahoo.comFirst Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical StudyApril 5, 2023 | finanznachrichten.deAvacta Group plc: Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyMarch 28, 2023 | finance.yahoo.comAvacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 16, 2023 | msn.comIs the Avacta share price dip a buying opportunity?January 17, 2023 | lse.co.ukBlock Listing Application to AIMOctober 21, 2022 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the companyOctober 1, 2022 | uk.finance.yahoo.comAvacta Group Plc (AVCT.L)September 5, 2022 | nasdaq.comAvacta's AVA6000 Gets FDA Orphan Drug Designation To Treat Soft Tissue Sarcoma; Stock UpJune 30, 2022 | finance.yahoo.comLG Chem Renews License Triggering Payment to AvactaMay 16, 2022 | benzinga.comAffyXell Expands its Strategic Partnership With...April 6, 2022 | proactiveinvestors.comAvacta full-year results push shares higherMarch 19, 2022 | finance.yahoo.comIs Avacta Group (LON:AVCT) In A Good Position To Invest In Growth?March 17, 2022 | uk.finance.yahoo.comWhat’s next for the Avacta share price?See More Headlines Receive AVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/28/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:AVCT CUSIPN/A CIKN/A Webwww.avacta.com Phone+44-1904-217070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-42,080,000.00 Net Margins-267.00% Pretax MarginN/A Return on Equity-143.33% Return on Assets-26.00% Debt Debt-to-Equity Ratio225.41 Current Ratio0.71 Quick Ratio4.96 Sales & Book Value Annual Sales£16.02 million Price / Sales9.50 Cash FlowGBX 2.89 per share Price / Cash Flow15.00 Book ValueGBX 8 per share Price / Book5.43Miscellaneous Outstanding Shares350,510,000Free FloatN/AMarket Cap£152.21 million OptionableNot Optionable Beta1.21 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. David Alastair Maclaughlin Smith (Age 58)CEO & Executive Director Comp: $444kMr. Tony Gardiner (Age 53)CFO, Company Secretary & Executive Director Comp: $273kDr. Christina Marie Coughlin B.S. (Age 54)M.D., Ph.D., Head of Research & Development, Interim Chief Medical Officer and Director Comp: $37kMs. Emma WrightGroup In-House CounselMr. Michael VinegradGroup Communications DirectorMr. R. Craig Slater FCA (Age 60)Chief Operating Officer of Diagnostics Comp: $69kDr. Matt JohnsonChief Scientific Officer of DiagnosticsDr. Fiona McLaughlin FSB (Age 54)Ph.D., Chief Scientific Officer of Therapeutics Division Mr. David WilsonChief Commercial Officer of DiagnosticsMs. Karen HarrisonChief Operating Officer of Therapeutics DivisionMore ExecutivesKey CompetitorsArix BioscienceLON:ARIXhVIVOLON:HVOOxford BiomedicaLON:OXBCircassia GroupLON:CIR4basebioLON:4BBView All Competitors AVCT Stock Analysis - Frequently Asked Questions How have AVCT shares performed in 2024? Avacta Group's stock was trading at GBX 116.50 at the beginning of the year. Since then, AVCT stock has decreased by 61.8% and is now trading at GBX 44.50. View the best growth stocks for 2024 here. How were Avacta Group's earnings last quarter? Avacta Group Plc (LON:AVCT) announced its quarterly earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) EPS for the quarter. Avacta Group had a negative net margin of 267.00% and a negative trailing twelve-month return on equity of 143.33%. What other stocks do shareholders of Avacta Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Amyris (AMRS). How do I buy shares of Avacta Group? Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:AVCT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
